Evidence map›Paper›PMID 38957186›Full record

ArticleFrontiers in neuroscience2024

Effects of cannabidiol, with and without ∆9-tetrahydrocannabinol, on anxiety-like behavior following alcohol withdrawal in mice.

Mariam Melkumyan, Vibha M Annaswamy, Alexandra M Evans, Opeyemi F Showemimo, Zari E McCullers, Dongxiao Sun, Terrence E Murphy, Kent E Vrana, Amy C Arnold, Wesley M Raup-Konsavage and 1 more

Abstract read
In one paragraph

Article in Frontiers in neuroscience, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Mariam MelkumyanThe Pennsylvania State University College of Medicine, Department of Neural and Behavioral Sciences, Hershey, PA, United States.
Vibha M AnnaswamyThe Pennsylvania State University College of Medicine, Department of Neural and Behavioral Sciences, Hershey, PA, United States.
Alexandra M EvansThe Pennsylvania State University College of Medicine, Department of Neural and Behavioral Sciences, Hershey, PA, United States.
Opeyemi F ShowemimoThe Pennsylvania State University College of Medicine, Department of Neural and Behavioral Sciences, Hershey, PA, United States.
Zari E McCullersThe Pennsylvania State University College of Medicine, Department of Neural and Behavioral Sciences, Hershey, PA, United States.
Dongxiao SunThe Pennsylvania State University College of Medicine, Department of Pharmacology, Hershey, PA, United States.
Terrence E MurphyThe Pennsylvania State University College of Medicine, Department of Public Health Sciences, Hershey, PA, United States.
Kent E VranaThe Pennsylvania State University College of Medicine, Department of Pharmacology, Hershey, PA, United States.
Amy C ArnoldThe Pennsylvania State University College of Medicine, Department of Neural and Behavioral Sciences, Hershey, PA, United States.
Wesley M Raup-KonsavageThe Pennsylvania State University College of Medicine, Department of Pharmacology, Hershey, PA, United States.
Yuval SilbermanThe Pennsylvania State University College of Medicine, Department of Neural and Behavioral Sciences, Hershey, PA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Alcohol use disorder (AUD) is commonly associated with anxiety disorders and enhanced stress-sensitivity; symptoms that can worsen during withdrawal to perpetuate continued alcohol use. Alcohol increases neuroimmune activity in the brain. Our recent evidence indicates that alcohol directly modulates neuroimmune function in the central amygdala (CeA), a key brain region regulating anxiety and alcohol intake, to alter neurotransmitter signaling. We hypothesized that cannabinoids, such as cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC), which are thought to reduce neuroinflammation and anxiety, may have potential utility to alleviate alcohol withdrawal-induced stress-sensitivity and anxiety-like behaviors via modulation of CeA neuroimmune function. Methods: We tested the effects of CBD and CBD:THC (3:1 ratio) on anxiety-like behaviors and neuroimmune function in the CeA of mice undergoing acute (4-h) and short-term (24-h) withdrawal from chronic intermittent alcohol vapor exposure (CIE). We further examined the impact of CBD and CBD:THC on alcohol withdrawal behaviors in the presence of an additional stressor. Results: We found that CBD and 3:1 CBD:THC increased anxiety-like behaviors at 4-h withdrawal. At 24-h withdrawal, CBD alone reduced anxiety-like behaviors while CBD:THC had mixed effects, showing increased center time indicating reduced anxiety-like behaviors, but increased immobility time that may indicate increased anxiety-like behaviors. These mixed effects may be due to altered metabolism of CBD and THC during alcohol withdrawal. Immunohistochemical analysis showed decreased S100β and Iba1 cell counts in the CeA at 4-h withdrawal, but not at 24-h withdrawal, with CBD and CBD:THC reversing alcohol withdrawal effects.. Discussion: These results suggest that the use of cannabinoids during alcohol withdrawal may lead to exacerbated anxiety depending on timing of use, which may be related to neuroimmune cell function in the CeA.

Indexed as

∆9-tetrahydrocannabinol (THC)alcohol withdrawalanxietyastrocytesCannabidiol (CBD)microgliaopen field test

Identifiers

PMID38957186
PMCPMC11217543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.